Stephen Zou

Practice Areas

Dr. Zou focuses mainly on intellectual property strategic consulting, patent portfolio management, patent infringement, validity, and freedom-to-operate opinions, due diligence, and dispute resolution; representing many multinational pharmaceutical companies, small and medium-sized innovative companies in handling intellectual property, drug regulatory matters and market admission related legal affairs.

The wide variety of technical areas in which Dr. Zou has obtained and enforced patent protection for clients include pharmacy, chemistry, and biotechnologies, as well as mechanical systems and medical devices.

Professional Memberships

All-China Patent Agents Association (ACPAA)

All China Lawyers Association (ACLA)

Association Internationale pour la Protection de la Propriété Intellectuelle (AIPPI)

Publications

- Claim definitions Undergoing Change, China IP Focus 2014, Managing Intellectual Property, 2014 [Co-authored]

- How to determine novelty-conferring features for a medical use claim, China IP Focus 2015, Managing Intellectual Property, 2015 [Co-authored]

- Disclosure requirements undergoing change, IAM Life Science (2015) [Co-authored]

- How to make sure your patent is properly supported in China, March 2016 [Co-author]

- Implications of recent life sciences cases in China, IAM Life Science March 2017 [Co-authored]

- Overview of regulatory reform in China, IAM Life Sciences, 2018. [Co-authored]

- Patent practice: recent developments in life sciences in China, IAM Life Sciences 2019, pp. 51-55 [Co-authored]

- Doctrine of equivalents for life science patents in China, IAM Life Sciences 2020, pp. 53-57 [Co-authored]

Languages Spoken

Chinese,English

Education

Work Highlights

Representative cases that Dr. Zou has led or participated include

- Defending titropium bromide patent portfolio for Boehringer Ingelheim (German) in the invalidation proceedings and in court procedures (5 patents involved, 2006-2012);

- Defending Candesartan Cilexetil patent portfolio for Takeda (Japan) in the invalidation proceedings and in court procedures ( 2 patents involved, 2007-2012);

- Representing Albis in Albis (Germany) vs. FTP China, invalidation & infringement cases (settled, 2012-2014);

- Representing Grundfos in Grundfos (Denmark) vs. Zhejiang Qianyuan (China), infringement case, the Beijing High Court (infringement found and damage awarded, 2013-2014);

- Representing Shanghai Cathay Biotech in Shanghai Cathay Biotech vs. Hilead Biotech (2013-2014) and won three administrative cases;

- Representing Xiamen Hongfa in Xiamen Hongfa (China) vs. Dou Xiuzhi (2013-2014) and winning two invalidation cases;

- Representing SEB in SEB (France) vs. Wenzhou Household electrical (2013-2014) and winning the invalidation case;

- Representing Shenzhen MINDRAY in Shenzhen MINDRAY vs. Edan (2013-2014) and winning in invalidation & administrative litigation;

- Representing Hongkong PolyU in Hongkong PolyU vs. Ritter machinery (2014) and winning the invalidation case;

- Representing Pfizer and successfully defending a polymorph case (2019).